Physician profile
Maria Rivera
NPI 1083233936
$519.45
in general payments reported to CMS, 2019-2025
14 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $130 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $519.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $100.90 | 2024-2025 | Farxiga, Airsupra |
| Abbvie INC. | $59.59 | 2025 | |
| Astellas Pharma US INC | $52.00 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $47.66 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $44.75 | 2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $41.03 | 2025 | Repatha, Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $34.12 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $28.21 | 2024 | |
| Pfizer INC. | $23.04 | 2025 | |
| Merck Sharp & Dohme LLC | $20.19 | 2025 | Capvaxive, Gardasil 9 |
| Lilly USA, LLC | $19.98 | 2025 | Mounjaro, Zepbound |
| Lundbeck LLC | $17.30 | 2025 | Rexulti |
| Janssen Biotech, INC. | $16.06 | 2025 | Tremfya |
| Kowa Pharmaceuticals America, INC. | $14.62 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.